CARES

Cabotegravir And Rilpivirine: Efficacy and Safety Study

Funders & Collaborative Partners

Funder & Collaborative Partner: Janssen Pharmaceutical Companies of Johnson & Johnson

Long-acting treatment options for HIV are a novel in the fight against the virus and offer people living with HIV valuable new choices for how they manage their care. Advances in the laboratory must be implemented at the last mile of healthcare delivery, which is why the work being done by the CARES team is vital to helping ensure that long-acting treatments reach people living with HIV.

Johnson & Johnson, in collaboration with ViiV Healthcare, is proud to be working alongside the JCRC team to help generate this critical data, which is investigating the impact on care and treatment outcomes for patients. We are proud of the work done so far and wish the team all the best as this study progresses.

Sincerely
Dr. Fafa Addo Boateng
Director, Data & Evidence Generation and Study/Molecule Responsible Physician

on behalf of Janssen Pharmaceutical Companies of Johnson & Johnson

Janssen

Dr Fafa Addo Boateng

Director Data and Evidence Generatiion

Willemijn Rein van Horst

Global Trial Leader

Dr. Fridah Mwendia

Clinical Research Manager- Evidence Generation Team Global Public Health, J&J

Dr. Lynne Klasko-Foster

Social and Implementation Scientist

Ukeh Idahosa

Evidence Generation Program Manager, Medical Affairs